Lenalidomide betapharm 15 mg, harde capsules

Country: Холандија

Језик: Холандски

Извор: CBG-MEB (College ter Beoordeling van Geneesmiddelen)

Активни састојак:

LENALIDOMIDE

Доступно од:

Betapharm Arzneimittel GmbH Kobelweg 95 D-86156 AUGSBURG (DUITSLAND)

АТЦ код:

L04AX04

INN (Међународно име):

LENALIDOMIDE

Фармацеутски облик:

Capsule, hard

Састав:

AMMONIA (E 527) ; CELLULOSE, MICROKRISTALLIJN (E 460) ; CROSCARMELLOSE NATRIUM (E 468) ; GELATINE (E 441) ; IJZEROXIDE ZWART (E 172) ; INDIGOKARMIJN (E 132) ; KALIUMHYDROXIDE (E 525) ; LACTOSE 0-WATER ; MAGNESIUMSTEARAAT (E 470b) ; PROPYLEENGLYCOL (E 1520) ; SCHELLAK (E 904) ; TITAANDIOXIDE (E 171) ; ZWARTE INKT

Пут администрације:

Oraal gebruik

Терапеутска област:

Lenalidomide

Датум одобрења:

2019-07-15

Информативни летак

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
LENALIDOMIDE BETAPHARM 2,5 MG, HARDE CAPSULES
LENALIDOMIDE BETAPHARM 5 MG, HARDE CAPSULES
LENALIDOMIDE BETAPHARM 7,5 MG, HARDE CAPSULES
LENALIDOMIDE BETAPHARM 10 MG, HARDE CAPSULES
LENALIDOMIDE BETAPHARM 15 MG, HARDE CAPSULES
LENALIDOMIDE BETAPHARM 20 MG, HARDE CAPSULES
LENALIDOMIDE BETAPHARM 25 MG, HARDE CAPSULES
lenalidomide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Lenalidomide betapharm is and what it is used for
2.
What you need to know before you take Lenalidomide betapharm
3.
How to take Lenalidomide betapharm
4.
Possible side effects
5.
How to store Lenalidomide betapharm
6.
Contents of the pack and other information
1
WHAT LENALIDOMIDE BETAPHARM IS AND WHAT IT IS USED FOR
Lenalidomide betapharm contains the active substance
‘lenalidomide’. This medicine belongs to a group of
medicines which affect how your immune system works.
Lenalidomide betapharm is used in adults for
•
Multiple Myeloma
•
Follicular lymphoma
MULTIPLE MYELOMA
Multiple myeloma is a type of cancer which affects a certain kind of
white blood cell, called the plasma cell.
These cells collect in the bone marrow and divide, becoming out of
control. This can damage the bones and
kidneys.
Multiple myeloma generally cannot be cured. However, the signs and
symptoms can be greatly reduced or
disappear for a period of time. This is called a ‘response’.
Newly diagnosed multiple myeloma - in patients who have had a bone
marrow transplant
Lenalidomide betapharm is used on

Карактеристике производа

SAMENVATTING VAN DE PRODUCTKENMERKEN
1.
NAME OF THE MEDICINAL PRODUCT
Lenalidomide betapharm 2,5 mg, harde capsules
Lenalidomide betapharm 5 mg, harde capsules
Lenalidomide betapharm 7,5 mg, harde capsules
Lenalidomide betapharm 10 mg, harde capsules
Lenalidomide betapharm 15 mg, harde capsules
Lenalidomide betapharm 20 mg, harde capsules
Lenalidomide betapharm 25 mg, harde capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains 2.5 mg of lenalidomide.
Each capsule contains 5 mg of lenalidomide.
Each capsule contains 7.5 mg of lenalidomide.
Each capsule contains 10 mg of lenalidomide.
Each capsule contains 15 mg of lenalidomide.
Each capsule contains 20 mg of lenalidomide.
Each capsule contains 25 mg of lenalidomide.
Excipient(s) with known effect:
Each capsule contains 33.2 mg of lactose.
Each capsule contains 66.4 mg of lactose.
Each capsule contains 99.7 mg of lactose.
Each capsule contains 132.9 mg of lactose.
Each capsule contains 199.3 mg of lactose.
Each capsule contains 265.8 mg of lactose.
Each capsule contains 332.2 mg of lactose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule.
Opaque white body and opaque green to light green cap, with a length
of approximately14.3 mm, marked
“L9NL” and “2.5”.
Opaque white body and opaque white cap, with a length of approximately
18.0 mm, marked “L9NL” and “5”.
Opaque white body and opaque yellow cap, with a length of
approximately 18.0 mm, marked “L9NL” and
“7.5”.
Opaque yellow body and opaque green to light green cap, with a length
of approximately 21.7 mm, marked
“L9NL” and “10”.
Opaque white body and opaque blue to light blue cap, with a length of
approximately 21.7 mm, marked “L9NL”
and “15”.
Opaque blue to light blue body and opaque green to light green cap,
with a length of approximately 21.7 mm,
marked “L9NL” and “20”.
Opaque white body and opaque white cap, with a length of approximately
21.7 mm, marked “L9NL” and “25”.
4.
CLINICAL PARTICULARS
4.1